Updates are available Correction dated 2023-07-20
Click to view Correction: https://doi.org/10.1038/s41467-023-40080-9
-
Authors
Troiani, Martina
Colucci, Manuel
D’Ambrosio, Mariantonietta
Guccini, Ilaria
Pasquini, Emiliano
Varesi, Angelica
Valdata, Aurora
Mosole, Simone
Revandkar, Ajinkya
Attanasio, Giuseppe
Rinaldi, Andrea
Rinaldi, Anna
Bolis, Marco https://orcid.org/0000-0003-4377-5079
Cippà, Pietro
Alimonti, Andrea https://orcid.org/0000-0002-9362-2313
- License Information
-
More Information
Article History
Received: 16 July 2021
Accepted: 24 March 2022
First Online: 21 April 2022
Change Date: 20 July 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-023-40080-9
Competing interests
: A.A. is a cofounder of and owns stock in OncoSense and A.A., M.C., and A.R. are inventors of the patent WO2019142095A1 (Title: new alk inhibitor senolytic drugs). The remaining authors declare no competing interests.
